Freedom Capital Markets has initiated coverage on Globus Medical Inc (GMED) with a Hold rating, marking the firm's first formal assessment of the company. The rating reflects an analysis of GMED's business fundamentals, industry conditions, and growth prospects.
Based in Audubon, Pennsylvania, Globus Medical operates as a medical device company specializing in healthcare solutions. The firm develops a range of differentiated technologies aimed at treating various musculoskeletal conditions, including both traditional fusion implants and innovative surgical instruments. With a current market capitalization of $11.6 billion, GMED reported a trailing twelve-month price-to-earnings ratio of 27.48 and earnings per share of 3.09.
The company is set to report its next earnings on February 10, 2026, with analysts estimating earnings per share of $1.11 and revenue of $792.1 million. This update provides insight into the current sentiment surrounding GMED, which has garnered a consensus rating of Buy among analysts, with 4 Strong Buy, 10 Buy, and 7 Hold ratings as of December 1, 2025.
Analyst ratings can fluctuate as new information emerges, and it is essential for investors to consider a variety of factors, including company performance and market trends, when making investment decisions.